Latest Cannabis And Psychedelic Medicines News

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.